CoChat

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody

Open access

The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.

Abstract

Significance: Anti–CTLA-4 mAb is able to augment tumor immunity despite CTLA-4 expression by functionally opposing T cell populations: activated effector T (Teff) cells and FOXP3 + CD4 + Treg cells. Here we show that anti–CTLA-4 mAb engineered to be cytotoxic depleted Treg cells effectively in vitro in humans and in vivo in mice. It expanded antigen-specific CD8 + Teff cells when tumor-antigen stimulation was delayed several days to protect them from killing by the mAb. Anti–CTLA-4 mAb modified to exhibit a lesser or no cell-depleting activity failed to show such effects. This strategy of differentially controlling Treg and Teff cells by cytotoxic anti–CTLA-4 mAb to evoke effective tumor immunity will help in designing cancer immunotherapy targeting other molecules commonly expressed by Treg and Teff cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1812186116

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 205

Metadata

Authors
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., Katayama, I., Nishikawa, H., & Sakaguchi, S.
Affiliations
  • Kyoto University (JP)
  • Immunology Frontier Research Center, The University of Osaka (JP)
  • Chugai Pharmaceutical Co., Ltd. (Japan) (JP)
  • The University of Osaka (JP)
  • Agency for Science, Technology and Research (SG)
Venue
Proceedings of the National Academy of Sciences
Published
2018-12-26
Volume
116
Issue
2
Pages
609-618
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2907885272
Cited by
205
References
37
Citations by year
2026: 11 · 2025: 25 · 2024: 31 · 2023: 22 · 2022: 41 · 2021: 24 · 2020: 33 · 2019: 17
FWCI
6.94
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • OUKA (Osaka University Knowledge Archive) (Osaka University) (submittedVersion)
Funders
  • MEXT | Japan Society for the Promotion of Science (16H006295)
  • Japan Agency for Medical Research and Development (JP18cm0106303)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
anti-CTLA-4 antibody, CTLA-4, regulatory T cells, Foxp3, effector T cells, CD8+ T cells, antitumor immunity, cancer immunotherapy, Fc-engineered antibody, antibody cytotoxicity, Treg depletion
MeSH terms
Antineoplastic Agents, Immunological, Animals, Antibody-Dependent Cell Cytotoxicity, Humans, Mice, Inbred BALB C, Neoplasms, CD8-Positive T-Lymphocytes, Cancer Vaccines, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody. https://app.cochat.ai/papers/10.1073/pnas.1812186116
The paper
Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., Katayama, I., Nishikawa, H., & Sakaguchi, S. (2019). Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1812186116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.